<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04986189</url>
  </required_header>
  <id_info>
    <org_study_id>CFTSp204</org_study_id>
    <nct_id>NCT04986189</nct_id>
  </id_info>
  <brief_title>Lung Screening in People Cured of Hodgkin Lymphoma</brief_title>
  <official_title>Lung Screening for Hodgkin Lymphoma Survivors: a Feasibility Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Christie NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Manchester</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The Christie NHS Foundation Trust</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A single site non-commercial study in which people treated for Hodgkin lymphoma survivors&#xD;
      will be invited to have a single low dose CT of thorax for lung cancer screening&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 1, 2021</start_date>
  <completion_date type="Anticipated">October 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary outcome: the lung cancer screening uptake rate among eligible individuals invited to the study</measure>
    <time_frame>Measured 6 months after recruitment begins when all interested participants have undergone a full eligibility check and those eligible have undergone their baseline low dose CT scan</time_frame>
    <description>Feasibility outcome</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Decisional conflict scores in those who receive the decision aid measured using the validated Decisional Conflict Scale (score 0-100 with higher score representing higher levels of decisional conflict)</measure>
    <time_frame>14 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preparedness for decision making in those who receive the decision aid using the validated Preparedness for Decision Making Scale (score 0-100 with higher score representing higher perceived levels of preparedness for decision making)</measure>
    <time_frame>4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lung cancer screening knowledge pre and post receipt of the decision aid measured using a novel scale (score 0-16 with higher score representing high levels of knowledge about lung cancer screening)</measure>
    <time_frame>4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion who have made an informed decision as measured by the Multidimensional Measure of Informed Choice</measure>
    <time_frame>6 and 12 months following CT scan</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anxiety levels pre and post screening measured using the State Trait Anxiety Inventory -6 validated scale (score 6-24 with higher score representing higher levels of anxiety)</measure>
    <time_frame>2 months post CT scan</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cancer worry severity levels pre and post screening measured using measured using 4-item Brief Worry Scale (score 4-20 with higher score representing higher cancer worry severity levels)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cancer worry frequency measured using intrusive thoughts subscale from Revised impact of events scale (score 6-30 with higher score representing more frequent cancer worry)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health related quality of life pre-screening then 6 and 12 months post screening measured using the validated SF-12 (short-form-12) scale (Scores range from 0 to 100, with higher scores indicating better physical and mental health functioning)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The rates of smoking cessation 6 and 12 months following screening</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The acceptability of undergoing screening measured using non-validated scale (Score 7-70 with higher score representing higher perceived acceptability of lung cancer screening)</measure>
    <time_frame>2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rates of normal, indeterminate and positive screening scans, reported according to definitions in the British Thoracic Society Pulmonary Nodule Management Guidelines</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The type and prevalence of incidental findings on screening scans</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The barriers and facilitators to undergoing lung cancer screening measured qualitatively and categorised according to the Theoretical Domains Framework</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Hodgkin Lymphoma</condition>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Invitation to have a low dose CT thorax</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>All participants are invited to undergo a low dose CT thorax</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Low dose CT thorax</intervention_name>
    <description>A low dose CT scan of the thorax to screen for lung cancer</description>
    <arm_group_label>Invitation to have a low dose CT thorax</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Aged 18-80&#xD;
&#xD;
          -  5 year or more survivor of HL&#xD;
&#xD;
          -  Any of: a) treated with radiotherapy for HL with radiation dose to the lung b) an&#xD;
             alkylating agent containing chemotherapy regimen known to increase lung cancer risk&#xD;
&#xD;
          -  Living within approximately 40 miles of The Christie Hospital&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous diagnoses of malignant neoplasm of trachea, bronchus, lung, thymus or pleura&#xD;
&#xD;
          -  A current diagnosis of metastatic cancer&#xD;
&#xD;
          -  Residents in nursing homes or housebound&#xD;
&#xD;
          -  Had a CT scan of the thorax within the last 12 months&#xD;
&#xD;
          -  Pregnant women&#xD;
&#xD;
          -  Unable to provide consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Rachel Broadbent, MD</last_name>
    <phone>07527546642</phone>
    <email>rachel.broadbent-2@postgrad.manchester.ac.uk</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Christie NHS Foundation Trust</name>
      <address>
        <city>Manchester</city>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <contact>
      <last_name>Kim Linton, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Rachel Broadbent, MBBCh</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>May 26, 2021</study_first_submitted>
  <study_first_submitted_qc>July 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 2, 2021</study_first_posted>
  <last_update_submitted>July 29, 2021</last_update_submitted>
  <last_update_submitted_qc>July 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>screening</keyword>
  <keyword>low dose CT scan</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

